WX8 Stock Overview
An investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs and advanced therapies in the People’s Republic of China, the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
WuXi AppTec Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥5.40 |
| 52 Week High | CN¥9.40 |
| 52 Week Low | CN¥3.16 |
| Beta | 0.81 |
| 11 Month Change | -12.20% |
| 3 Month Change | 50.84% |
| 1 Year Change | -49.06% |
| 33 Year Change | -68.97% |
| 5 Year Change | -10.18% |
| Change since IPO | 66.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| WX8 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -8.5% | 0.9% | -0.02% |
| 1Y | -49.1% | 2.7% | 8.2% |
Return vs Industry: WX8 underperformed the German Life Sciences industry which returned 2% over the past year.
Return vs Market: WX8 underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| WX8 volatility | |
|---|---|
| WX8 Average Weekly Movement | 16.3% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: WX8's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: WX8's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 38,134 | Ge Li | www.wuxiapptec.com |
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs and advanced therapies in the People’s Republic of China, the United States, Europe, and internationally. The company operates in six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic.
WuXi AppTec Co., Ltd. Fundamentals Summary
| WX8 fundamental statistics | |
|---|---|
| Market cap | €18.65b |
| Earnings (TTM) | €1.07b |
| Revenue (TTM) | €5.10b |
17.8x
P/E Ratio3.7x
P/S RatioIs WX8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WX8 income statement (TTM) | |
|---|---|
| Revenue | CN¥38.50b |
| Cost of Revenue | CN¥22.86b |
| Gross Profit | CN¥15.64b |
| Other Expenses | CN¥7.57b |
| Earnings | CN¥8.06b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.79 |
| Gross Margin | 40.61% |
| Net Profit Margin | 20.94% |
| Debt/Equity Ratio | 10.1% |
How did WX8 perform over the long term?
See historical performance and comparison